Influenza Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Influenza Tests market for the year 2020 and beyond. Influenza, also called flu or grippe, is an acute viral infection of the upper or lower respiratory tract that is marked by fever, chills, and a generalized feeling of weakness and pain in the muscles, together with varying degrees of soreness in the head and abdomen. Influenza viruses are categorized as types A, B, C, and D.
For the purpose of this model, infections have been defined as definitively reported positive tests, such as those reported by the World Health Organization FluNet. Data to this resource have been provided remotely to the WHO by the National Influenza Centres (NICs) of the Global Influenza Surveillance and Response System (GISRS) and other reference laboratories actively collaborating with the GISRS.
Influenza Tests Model includes Influenza Antigen Tests, Lowplex Nucleic Acid Amplification Tests (NAATs) and Multiparameter Nucleic Acid Amplification Tests (NAATs).
Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Influenza Test and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
The model discusses in detail the impact of COVID-19 on Influenza Tests market for the year 2020 and beyond. Influenza, also called flu or grippe, is an acute viral infection of the upper or lower respiratory tract that is marked by fever, chills, and a generalized feeling of weakness and pain in the muscles, together with varying degrees of soreness in the head and abdomen. Influenza viruses are categorized as types A, B, C, and D.
For the purpose of this model, infections have been defined as definitively reported positive tests, such as those reported by the World Health Organization FluNet. Data to this resource have been provided remotely to the WHO by the National Influenza Centres (NICs) of the Global Influenza Surveillance and Response System (GISRS) and other reference laboratories actively collaborating with the GISRS.
Influenza Tests Model includes Influenza Antigen Tests, Lowplex Nucleic Acid Amplification Tests (NAATs) and Multiparameter Nucleic Acid Amplification Tests (NAATs).
Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Influenza Test and evolving competitive landscape:
- Insightful review of the key industry trends.
- Annualized total Influenza Tests market revenue by segment and market outlooks from
- Market level data on units, average selling prices and market values.
Global, Regional and Country level market specific insights:
- Qualitative market specific information is available with global trends further broken down into regional trends. In addition, the publisher analysts provide unique country specific insights on the market.
- SWOT analysis for Influenza Tests market.
- Competitive dynamics insights and trends provided for Influenza Tests market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country specific overview of the healthcare system.
- Country specific reimbursement policies.
- Country specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Abbott Laboratories, Danaher Corp, Quidel Corp, F. Hoffmann-La Roche Ltd, DiaSorin SpA, Becton Dickinson and Co, Qiagen NV, Thermo Fisher Scientific Inc and Others
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
Scope
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
- CMO executives who must have deep understanding of the Influenza Tests market place to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
The model will enable you to -
- Understand the impact of COVID-19 on Influenza Tests market.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving Influenza Tests market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Influenza Tests market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track device sales in the global and country-specific Influenza Tests market from 2015-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Danaher Corp
- Quidel Corp
- F. Hoffmann-La Roche Ltd
- DiaSorin SpA
- Becton Dickinson and Co
- Qiagen NV
- Thermo Fisher Scientific Inc